Bosutinib

Chemical formula: C₂₆H₂₉Cl₂N₅O₃  Molecular mass: 530.446 g/mol  PubChem compound: 5328940

Therapeutic indications

Bosutinib is indicated for:

Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML)

Population group: only adults (18 years old or older)

Bosutinib is indicated for the treatment of adult patients with:

  • newly-diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML).
  • CP, accelerated phase (AP), and blast phase (BP) Ph+ CML previously treated with one or more tyrosine kinase inhibitor(s) [TKI] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2019: BOSULIF Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈